uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration
Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece.;Hygeia Gen Hosp, 4 Erythrou Stavrou Str & Kifisias, Athens 15123, Greece..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece..
Hygeia Gen Hosp, 4 Erythrou Stavrou Str & Kifisias, Athens 15123, Greece..
Show others and affiliations
2016 (English)In: International Journal of Antimicrobial Agents, ISSN 0924-8579, E-ISSN 1872-7913, Vol. 48, no 3, 337-341 p.Article in journal (Refereed) Published
Abstract [en]

Traditionally, reduced daily doses of colistin methanesulphonate (CMS) in critically ill patients receiving continuous venovenous haemodiafiltration (CVVHDF) have resulted in suboptimal colistin concentrations. The necessity of a loading dose (LD) at treatment initiation has been proposed. A LD of 9 million IU (MU) [ca. 270 mg of colistin base activity (CBA)] was administrated with a maintenance dose of 4.5 MU (ca. 140 mg CBA) every 12 h (q12h) to eight critically ill patients receiving renal replacement therapy. Blood samples were collected immediately before and at different time intervals after the LD and the fourth dose, whilst pre-filter and post-filter blood samples were also collected. CMS and colistin concentrations were determined using an LC-MS/MS assay. Median maximum observed concentrations after the LD were 22.1 mg/L for CMS and 1.55 mg/L for colistin, whereas during maintenance dosing the corresponding values were 12.6 mg/L and 1.72 mg/L, respectively. CVVHDF clearance was determined as 2.98 L/h for colistin, equivalent to 62% of total apparent colistin clearance in CVVHDF patients. Both CMS and colistin were cleared by CVVHDF. Application of a LD of 9 MU CMS resulted in more rapid achievement of the target colistin concentration. Following implementation of a predicted pharmacokinetic model on plasma CMS/colistin concentrations, a LD of 12 MU CMS appears more appropriate, whilst a CMS maintenance dosage of at least 6.5-7.5 MU q12h is suggested in patients undergoing CVVHDF. However, further clinical studies are warranted to assess the safety of a LD of 12 MU CMS in patients receiving CVVHDF.

Place, publisher, year, edition, pages
2016. Vol. 48, no 3, 337-341 p.
Keyword [en]
Colistin, CMS, Loading dose, Pharmacokinetics, CVHHDF
National Category
Pharmaceutical Sciences Infectious Medicine
Identifiers
URN: urn:nbn:se:uu:diva-308782DOI: 10.1016/j.ijantimicag.2016.06.008ISI: 000386022000018PubMedID: 27474468OAI: oai:DiVA.org:uu-308782DiVA: diva2:1054601
Available from: 2016-12-08 Created: 2016-11-30 Last updated: 2016-12-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Friberg, Lena E
By organisation
Department of Pharmaceutical Biosciences
In the same journal
International Journal of Antimicrobial Agents
Pharmaceutical SciencesInfectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 54 hits
ReferencesLink to record
Permanent link

Direct link